Cargando…
Effect of TAAR1/5-HT(1A) agonist SEP-363856 on REM sleep in humans
SEP-363856 is a trace amine-associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT(1A)) agonist, currently in Phase 3 clinical trials for the treatment of schizophrenia. Although SEP-363856 activates TAAR1 and 5-HT(1A) receptors in vitro, an accessible marker of time- and concentration-...
Autores principales: | Hopkins, Seth C., Dedic, Nina, Koblan, Kenneth S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058073/ https://www.ncbi.nlm.nih.gov/pubmed/33879769 http://dx.doi.org/10.1038/s41398-021-01331-9 |
Ejemplares similares
-
TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT(1A) receptor agonist SEP-363856
por: Saarinen, Marcus, et al.
Publicado: (2022) -
Correction To: TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT(1A) receptor agonist SEP- 363856
por: Saarinen, Marcus, et al.
Publicado: (2022) -
The Potential Antidepressant Action of Duloxetine Co-Administered with the TAAR1 Receptor Agonist SEP-363856 in Mice
por: Ren, Xia, et al.
Publicado: (2022) -
In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics
por: Ågren, Richard, et al.
Publicado: (2023) -
M208. MEASURES OF COGNITION AND SOCIAL FUNCTIONING IN SCHIZOPHRENIA PATIENTS RECEIVING SEP-363856
por: Milanovic, Snezana, et al.
Publicado: (2020)